- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Alzheimer patients likely to benefit from acetylcholinesterase inhibitors in reducing AMD risk: JAMA
Age-related macular degeneration (AMD) is a prevalent ophthalmologic condition hypothesised to involve inflammation in the macula. The use of acetylcholinesterase inhibitors (AChEIs) for Alzheimer's disease treatment may have anti-inflammatory effects, but it is unclear if they modify AMD risk.
An original investigation published in JAMA Ophthalmology concluded that AChEIs could help lower the risk of AMD. They found that AD patients on AChEIs had a slightly lower hazard of AMD development compared to untreated patients. AChEIs reduced AMD risk, while memantine showed no association with AMD incidence.
Does using acetylcholinesterase inhibitors (AChEIs), commonly prescribed for Alzheimer's disease, influence the incidence of age-related macular degeneration? This study investigated the association between AChEI medications and the incidence of AMD.
This retrospective cohort study was conducted at healthcare facilities within the US Department of Veterans Affairs (VA) healthcare system (from January 2000 to September 2023). Patients aged 55-80 with AD and no prior AMD diagnosis in the VA database were included in this investigation. Exposure was AChEIs prescribed for AD treatment, and the outcome was the first diagnosis of AMD.
The results of this investigation are:
- A total 21 823 veterans with AD, with a mean age of 72.3 years, were included.
- A total of 21 313 male and 510 female participants were included.
- As the Propensity score–matched the Cox model revealed, each additional year of AChEI treatment was tied to a 6% lower hazard of AMD (hazard ratio, 0.94).
This study found a slight decrease in AMD risk for veterans with AD taking AChEIs. More research is needed to confirm cause and effect and validate these results across diverse populations.
Reference:
Sutton SS et al. Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration. JAMA Ophthalmol. Published online January 04, 2024. doi:10.1001/jamaophthalmol.2023.6014
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751